{"id":"NCT01541371","sponsor":"Xian-Janssen Pharmaceutical Ltd.","briefTitle":"A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia","officialTitle":"An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Non Acute Episode Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2012-02-29","resultsPosted":"2013-08-07","lastUpdate":"2013-08-07"},"enrollment":405,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone ER","otherNames":[]}],"arms":[{"label":"Paliperidone ER","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \\[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\\] and hallucinations \\[imagining things\\], and withdrawal into the self) who were not satisfied with other prior antipsychotics (agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect; olanzapine, quetiapine and risperidone) they had been taking. The safety and tolerability of paliperidone ER tablets will also be assessed.","primaryOutcome":{"measure":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Lack of Efficacy Group","deltaMin":77.18,"sd":17.5},{"arm":"Lack of Tolerability Group","deltaMin":58.46,"sd":16.31},{"arm":"Other Group","deltaMin":63.33,"sd":19.08}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":403},"commonTop":["Akathisia","Tremor","Dystonia","Somnolence","Insomnia"]}}